Hookipa raises $37.4M series D

Hookipa Pharma Inc. (New York, N.Y.) raised $37.4 million (€33 million) on Feb. 26 in a series D round led by Redmile Group. The company is developing a pipeline of vaccines based on its VaxWave and TheraT viral vector platforms.

Hookipa's HB-101 is in a Phase II study to prevent cytomegalovirus (CMV) infection in kidney transplantation patients. The bivalent vaccine uses VaxWave vectors to express CMV pp65 and truncated CMV glycoprotein B...